Loading
A phase 2 trial of Pimicotinib (ABSK021) in pancreatic ductal adenocarcinoma, run by Abbisko Therapeutics Co, Ltd, now recruiting.
A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer is a phase 2 interventional study registered as NCT06111274 by Abbisko Therapeutics Co, Ltd, with 82 participants planned, started 2023-10-17 and due to reach its primary completion in 2025-12-30. Interventions recorded: Pimicotinib (ABSK021).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Abbisko Therapeutics and the tag pipeline.
Shares Abbisko Therapeutics and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Abbisko Therapeutics and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/